CLINICAL TRIAL SUMMARY

MDACC Study No:2003-0696 (clinicaltrials.gov NCT No: NCT00387023)
Title:Pilot trial of Radioimmunotherapy with Yttrium 90-Labeled (90Y) Zevalin for Low-Grade Follicular Non-Hodgkin's Lymphoma or MALT of the Orbit/Conjunctiva
Principal Investigator:Bita Esmaeli
Treatment Agent:90Y-ibritumomab tiuxetan; Rituxan; Rituximab; Zevalin
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if giving Rituxan
(rituximab) and Zevalin may be effective in controlling orbital lymphoma
(cancer of the eye socket). The safety of treatment with Zevalin will also be
studied.

Hide details for General InformationGeneral Information

Disease Group:Eye; Lymphoma
Phase of Study:N/A
Treatment Agents:90Y-ibritumomab tiuxetan
Rituxan
Rituximab
Zevalin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Participants should return to MDACC on a weekly to monthly basis.
Home Care:None


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Bita Esmaeli
Dept:Ophthalmology/Head & Neck Surgery
For Clinical Trial Enrollment:713-792-6920
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults